Amgen Scoffs At Roche Proposal In EPO Patent Battle

Law360, New York (February 21, 2008, 12:00 AM EST) -- Amgen Inc. reiterated its desire for a permanent injunction barring F. Hoffman-La Roche Ltd.'s anemia treatment Mircera from the U.S. market, in response to the Swiss company's proposal to make the peg-EPO product available to patients in America and pay Amgen a 20% royalty on Mircera's U.S. sales.

Amgen filed a brief on Tuesday comparing Roche to a “snake-oil salesman” and arguing that U.S. District Judge William G. Young should issue an injunction barring Roche from selling any peg-EPO product in the U.S. for the term...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.